Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

• Phase: Phase 4

Details

• Lead Sponsor: Innovative Medical
• Treatments: Brimonidine Tartrate; Dorzolamide; Latanoprost

Criteria

Inclusion Criteria:

• · Male or female > 18 years of age

• Diagnosis of open-angle glaucoma or ocular hypertension

• IOP > 16 mm Hg in each eye at the latanoprost -treated baseline evaluation

• Presently on latanoprost monotherapy for at least 6 weeks

• Ability to provide informed consent and likely to complete all study visits

Exclusion Criteria:

• · Known contraindication or allergy to brimonidine or any of its components

• Subjects must be naive to brimonidine 0.2% or brimonidine Purite 0.15% and dorzolamide 2%

• Uncontrolled systemic disease

• Active ocular disease other than glaucoma or ocular hypertension (e.g. uveitis, ocular infections, or severe dry eye). Patients with chronic mild blepharitis, cataract, age-related macular degeneration, or background diabetic retinopathy may be enrolled at the discretion of the investigator.

• Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear product is allowed).

• Corneal abnormalities

• History of intraocular surgery within the last 3 months

• Female patients of childbearing potential who are pregnant, lactating, planning a pregnancy, or not using a reliable form of birth control

• Visual field loss, which in the opinion of the investigator, is functionally significant, or evidence of progressive visual field loss within the last year.